Last reviewed · How we verify
pPJV7630 administered by PMED — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
pPJV7630 administered by PMED (pPJV7630 administered by PMED) — PowderMed.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| pPJV7630 administered by PMED TARGET | pPJV7630 administered by PMED | PowderMed | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- pPJV7630 administered by PMED CI watch — RSS
- pPJV7630 administered by PMED CI watch — Atom
- pPJV7630 administered by PMED CI watch — JSON
- pPJV7630 administered by PMED alone — RSS
Cite this brief
Drug Landscape (2026). pPJV7630 administered by PMED — Competitive Intelligence Brief. https://druglandscape.com/ci/ppjv7630-administered-by-pmed. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab